Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Obstructive Sleep Apnea Syndrome in Glaucoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00313092
Recruitment Status : Terminated (recruiting problems)
First Posted : April 11, 2006
Last Update Posted : October 2, 2015
Sponsor:
Collaborator:
University Hospital, Basel, Switzerland
Information provided by (Responsible Party):
Selim Orguel, University Hospital, Basel, Switzerland

Brief Summary:
The aim of the study is to determine if plasma matrix-metalloproteinase activity can predict glaucoma in patients with OSAS and if the level of plasma matrix-metalloproteinase activity will decrease after one month of nCPAP-treatment.

Condition or disease Intervention/treatment
Obstructive Sleep Apnea Syndrome Glaucoma Device: nCPAP treatment

Detailed Description:
Glaucoma is a leading cause of blindness world-wide. Chronic primary open-angle glaucoma is the most common form among Caucasian patients. The key feature of glaucoma is damage to the optic nerve head, which is not necessarily related to an increased intraocular pressure. The prevalence of glaucoma among the patients with sleep apnoea was 7,2%: normal-tension glaucoma 2,9%, primary open-angle glaucoma 4,3%. The prevalence of obstructive sleep apnoea syndrome (OSAS) is around 4-10% for men and 2-4% for women. Matrix metalloproteinases (MMPs) substrates include essentially all extracellular matrix components as well as a wide array of molecules involved in intracellular adhesion, cell-matrix interaction, and cell signalling. However, MMPs effects are not restricted to extracellular matrix degradation. The prevalence of increased MMP in patients with OSAS and its predicting value for an additional glaucoma are not known. Further, we do not know if treatment of OSAS with nasal continuous positive air pressure(nCPAP) can decrease the MMP activity. With this study, we want to determine the prevalence of MMP activity and the prevalence of glaucoma in patients with OSAS. Further, we want to investigate if a nCPAP treatment period of four weeks decreases the MMP activity.

Layout table for study information
Study Type : Observational
Actual Enrollment : 60 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Does Plasma Matrix-metalloproteinase Activity Predict Glaucomas in Patients With OSAS (Obstructive Sleep Apnea Syndrome) and Does the Level of Plasma Matrix-metalloproteinase Activity Decrease After One Month of nCPAP-treatment
Study Start Date : January 2005
Actual Primary Completion Date : September 2005
Actual Study Completion Date : September 2005

Resource links provided by the National Library of Medicine



Intervention Details:
  • Device: nCPAP treatment
    treatment with positive air pressure during night


Biospecimen Retention:   None Retained
plasma


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 95 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with sleep apnoe syndrom
Criteria

Inclusion Criteria:

  • OSAS planned begin of a nCPAP treatment

Exclusion Criteria:

  • Current malignancy
  • Oral steroids

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00313092


Locations
Layout table for location information
Switzerland
University Hospital Basel, Eye Clinic
Basel, BS, Switzerland, 4031
Sponsors and Collaborators
Selim Orguel
University Hospital, Basel, Switzerland
Investigators
Layout table for investigator information
Study Director: Selim Orgül, MD University Eye Clinic Basel

Layout table for additonal information
Responsible Party: Selim Orguel, Prof. Dr., University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT00313092     History of Changes
Other Study ID Numbers: 045-LEJ-2004-002
First Posted: April 11, 2006    Key Record Dates
Last Update Posted: October 2, 2015
Last Verified: October 2015

Keywords provided by Selim Orguel, University Hospital, Basel, Switzerland:
OSAS
glaucoma
MMP

Additional relevant MeSH terms:
Layout table for MeSH terms
Apnea
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Glaucoma
Syndrome
Disease
Pathologic Processes
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Ocular Hypertension
Eye Diseases